Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 778-784

  Selmayr, M ^a   Strehl, J ^a   Kremer, J P ^b   Kremmer, E ^a   Doenecke, A ^d   Hallek, M ^d   Menzel, H ^c,f   Thielemans, K ^e   Thierfelder, S ^a   Mocikat, R ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Experimentelle Hämatologie   (Germany)

^c Klinische Hämatologie   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

B cell lymphoma; Gene therapy; GM CSF; Homologous recombination

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN IDIOTYPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNIZATION; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENE THERAPY; IMMUNOGLOBULIN GENE; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT GENE; TUMOR IMMUNITY;

ANIMALS; ANTIBODY FORMATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 6544295248     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300875     Document Type: Article

References (36)

1. Coulie PG. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 1997; 3: 261-268.
2. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-729.
3. Tsioulias GJ et al. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon. Cancer Res 1993; 53: 2374-2378.
4. Chen L et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
5. Schwartz RH. A cell culture mode] for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356.
6. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 1990; 65: 800-814.
7. Schiller JH et al. A direct comparison of immunological and clinical effects of interleukin-2 with and without interferon-α in humans. Cancer Res 1993; 53: 1286-1292.
8. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25: 1137-1140.
9. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
10. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
11. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
12. Steinmann RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
13. Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
14. Campbell MJ et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145: 1029-1036.
15. George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988; 141: 2168-2174.
16. Campbell MJ et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139: 2825-2833.
17. Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16: 199-210.
18. Kwak LW et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New Engl J Med 1992; 327: 1209-1215.
19. Tao M-H, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755-758.
20. Mocikat R et al. Unaltered immunoglobulin expression in hybridoma cells modified by targeting of the heavy chain locus with an integration vector. Immunology 1995; 84: 159-163.
21. Kardnal C et al. Integration vectors for antibody chimerization by homologous recombination in hybridoma cells. Eur J Immunol 1995; 25: 792-797.
22. Mocikat R, Kütemeier G, Hoffmann-Fezer G, Thierfelder S. A mouse model for the preclinical evaluation of immunosuppressive effector functions of human isotypes. The human IgG1 isotype is superior to IgG3. Transplantation 1994; 57: 405-411.
23. Chace JH, Cowdery JS, Field EH. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol 1994; 152: 405-412.
24. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 1996; 2: 1038-1041.
25. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res 1997; 57: 2346-2349.
26. Stanley E et al. The structure and expression of the murine gene encoding granulocyte-macrophage colony-stimulating factor: evidence for utilisation of alternative promoters. EMBO J 1985; 4: 2569-2573.
27. Mocikat R, Kardinal C, Klobeck, HG. Differential interactions between the immunoglobulin heavy chain μ intron and 3′ enhancer. Eur J Immunol 1995; 25: 3195-3198.
28. 5 pre-B cell-specific genes can associate with each other and with μ heavy chain. J Exp Med 1990; 172: 969-972.
29. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977; 7: 413-417.
30. Kim KJ et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979; 122: 549-554.
31. Laskov R, Scharff MD. Synthesis, assembly and secretion of gamma globulin by mouse myeloma cells. I. Adaptation of the Merwin plasma cell tumor-11 to culture, cloning and characterization of gamma globulin subunits. J Exp Med 1970; 131: 515-541.
32. Shulman M, Wilde CD, Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269-270.
33. Demanet C et al. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 1991; 147: 1091-1097.
34. Naparstek E et al. Induction of growth alterations in factor-dependent hematopoietic progenitor cell lines by cocultivation with irradiated bone marrow stromal cell lines. Blood 1986; 67: 1395-1403.
35. Reinecke K, Mysliwietz J, Thierfelder S. Single as well as pairs of synergistic anti-CD4 + CD8 antibodies prevent graft-versus-host disease in fully mismatched mice. Transplantation 1994; 57: 458-461.
36. Kremmer E et al. Neutralization of immunosuppression by antibodies against variable as well as constant regions of monoclonal anti-Thy-1 xenoantibodies and their ability to be suppressed by initial T cell depletion. Transplantation 1989; 47: 641-646.